论文部分内容阅读
目的 2型糖尿病(T2DM)是由于胰岛素抵抗以及胰岛B细胞缺陷而形成的以空腹以及餐后高血糖为主要特征的代谢异常综合征。肥胖常是2型糖尿病(T2DM)的伴随和前导因素。而那格列奈(唐力)为餐时血糖调节剂,有效降低餐后血糖;二甲双胍可以减少肝糖的输出,减轻体重,改善胰岛素抵抗,有效降低空腹血糖。本文旨在观察那格列奈联合二甲双胍治疗新诊断肥胖2型糖尿病(T2DM)患者的有效性与安全性。
Purpose Type 2 diabetes mellitus (T2DM) is a metabolic syndrome characterized by fasting and postprandial hyperglycemia due to insulin resistance and islet B cell defects. Obesity is often a companion and leading factor for type 2 diabetes (T2DM). And nateglinide (Tang force) as a mealtime blood glucose regulator, effectively reducing postprandial blood glucose; metformin can reduce the output of glycogen, reduce weight, improve insulin resistance, effectively reduce fasting blood glucose. This article aims to observe the efficacy and safety of nateglinide in combination with metformin in the treatment of newly diagnosed type 2 diabetes mellitus (T2DM) in patients with obesity.